Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity

Clin Cancer Res. 2016 Nov 1;22(21):5164-5166. doi: 10.1158/1078-0432.CCR-16-1666. Epub 2016 Aug 12.

Abstract

Oncolytic viruses, proteasome inhibitors, and natural killer (NK)-cell immunotherapy have all been studied extensively as monotherapies but have never been evaluated in combination. Synergetic treatment of oncolytic virus-infected glioblastomas with a proteasome inhibitor induces necroptotic cell death to enhance NK-cell immunotherapy, prolonging survival against human glioblastoma. Clin Cancer Res; 22(21); 5164-6. ©2016 AACRSee related article by Yoo et al., p. 5265.

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Bortezomib / therapeutic use*
  • Cell Death / drug effects
  • Cell Death / immunology
  • Combined Modality Therapy / methods
  • Cytotoxicity, Immunologic / immunology
  • Glioblastoma / drug therapy
  • Glioblastoma / immunology*
  • Herpesvirus 1, Human / immunology*
  • Humans
  • Immunotherapy / methods
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / immunology*
  • Oncolytic Virotherapy / methods
  • Oncolytic Viruses / immunology*
  • Proteasome Inhibitors / therapeutic use

Substances

  • Antineoplastic Agents
  • Proteasome Inhibitors
  • Bortezomib